HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Interferon alpha for the treatment of advanced renal cancer.

Abstract
This paper is an overview on the place of IFN-alpha in metastatic renal cell carcinoma (MRCC). After a presentation of MRCC and the mode of action of IFN-alpha, the results of studies including IFN-alpha alone or in combination with IL-2, chemotherapy and other biological modifiers are presented. Finally, new trends for new drugs, including antiangiogenic therapies, are discussed.
AuthorsAlain Ravaud, Marie-Sarah Dilhuydy
JournalExpert opinion on biological therapy (Expert Opin Biol Ther) Vol. 5 Issue 6 Pg. 749-62 (Jun 2005) ISSN: 1744-7682 [Electronic] England
PMID15952906 (Publication Type: Journal Article, Review)
Chemical References
  • Angiogenesis Inhibitors
  • Antimetabolites, Antineoplastic
  • Interferon-alpha
  • Interleukin-2
  • Fluorouracil
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Carcinoma, Renal Cell (blood supply, surgery, therapy)
  • Combined Modality Therapy
  • Fluorouracil (therapeutic use)
  • Humans
  • Interferon-alpha (therapeutic use)
  • Interleukin-2 (therapeutic use)
  • Kidney Neoplasms (blood supply, surgery, therapy)
  • Neoplasm Metastasis
  • Neovascularization, Pathologic (therapy)
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: